NRSN2 promotes breast cancer metastasis by activating PI3K/AKT/mTOR and NF-κB signaling pathways

被引:23
|
作者
Ren, Fei [1 ]
Zhang, Wei [1 ]
Lu, Shuai [1 ]
Ren, Hong [2 ]
Guo, Yantong [1 ]
机构
[1] Peking Univ, Dept Med, 38 Xueyuan Rd, Beijing 100191, Peoples R China
[2] Shanxi Tradit Chinese Med Univ, Affiliated Hosp, Dept Breast Surg, Taiyuan 030024, Shanxi, Peoples R China
关键词
neurensin-2; breast cancer; proliferat on; PI3K/AKT/mTOR; NF-kappa B; EXPRESSION; SURVIVAL; MARKERS; GENES; TUMOR; RATES;
D O I
10.3892/ol.2019.11152
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Breast cancer is a leading cause of cancer-associated mortality globally amongst gynecologic tumors due to aggressive metastasis. A previous study reported that neurensin-2 (NRSN2) was implicated in human cancer cells, and that NRSN2 gene and protein expression levels were significantly upregulated in human breast cancer tissues compared with adjacent non-tumor tissues. The purpose of the present study was to analyze the role of NRSN2 in the metastasis of breast cancer cells and explore its potential mechanism. Reverse transcription-quantitative PCR, MTT, western blotting and immunohistochemistry was used to analyze the role of NRSN2 both in vitro and in vivo. The present study demonstrated that NRSN2 knockdown inhibited the proliferation, migration and invasion of breast cancer cells in vitro. NRSN2 upregulation promoted breast cancer cell proliferation and tissue growth in vitro and in vivo. In addition, the results demonstrated that the regulatory effects of NRSN2 on breast cancer cells were associated with PI3K/AKT/mTOR and NF-kappa B signaling pathway dysregulation. Furthermore, NRSN2 overexpression in mice significantly promoted breast cancer cell proliferation. In conclusion, the results from the present study indicated that NRSN2 may be considered as a novel oncogenic protein and may represent a potential therapeutic target for breast cancer.
引用
收藏
页码:813 / 823
页数:11
相关论文
共 50 条
  • [31] PLEK2 promotes osteosarcoma tumorigenesis and metastasis by activating the PI3K/AKT signaling pathway
    Liu, Yang
    Yang, Siting
    Wang, Feng
    Zhou, Zheng
    Xu, Wenjing
    Xie, Jingjing
    Qiao, Linhui
    Gu, Yanglin
    ONCOLOGY LETTERS, 2021, 22 (01)
  • [32] AKR1B10 promotes breast cancer cell proliferation and migration via the PI3K/AKT/NF-κB signaling pathway
    Qu, Jiayao
    Li, Jia
    Zhang, Yaming
    He, Rongzhang
    Liu, Xiangting
    Gong, Ke
    Duan, Lili
    Luo, Weihao
    Hu, Zheng
    Wang, Gengsheng
    Xia, Chenglai
    Luo, Dixian
    CELL AND BIOSCIENCE, 2021, 11 (01):
  • [33] AKR1B10 promotes breast cancer cell proliferation and migration via the PI3K/AKT/NF-κB signaling pathway
    Jiayao Qu
    Jia Li
    Yaming Zhang
    Rongzhang He
    Xiangting Liu
    Ke Gong
    Lili Duan
    Weihao Luo
    Zheng Hu
    Gengsheng Wang
    Chenglai Xia
    Dixian Luo
    Cell & Bioscience, 11
  • [34] Effects of vaspin on pancreatic β cell secretion via PI3K/Akt and NF-κB signaling pathways
    Liu, Shiwei
    Li, Xin
    Wu, Yaru
    Duan, Ruixue
    Zhang, Jiaxin
    Dui, Fang
    Zhang, Qi
    Li, Yuanbin
    Li, Naishi
    PLOS ONE, 2017, 12 (12):
  • [35] Vaspin Improves Islet β-Cell Function via PI3K/Akt and NF-κB Signaling Pathways
    Liu Shiwei
    Li Xin
    Du Fang
    Duan Ruixue
    Wu Yaru
    Zhang Jiaxin
    Zhang Qi
    DIABETES, 2017, 66 : A584 - A584
  • [36] PI3K/Akt/mTOR inhibitors in breast cancer
    Joycelyn JX Lee
    Kiley Loh
    Yoon-Sim Yap
    Cancer Biology & Medicine, 2015, (04) : 342 - 354
  • [37] PI3K/Akt/mTOR inhibitors in breast cancer
    Lee, Joycelyn J. X.
    Loh, Kiley
    Yap, Yoon-Sim
    CANCER BIOLOGY & MEDICINE, 2015, 12 (04) : 342 - 354
  • [38] The PI3K/AKT/mTOR signaling pathway: Implications in the treatment of breast cancer
    Andreopoulou E.
    Current Breast Cancer Reports, 2011, 3 (1) : 63 - 74
  • [39] ERCC6L promotes the progression of hepatocellular carcinoma through activating PI3K/AKT and NF-κB signaling pathway
    Chen, Han
    Wang, Hengxiao
    Yu, Xiqiao
    Zhou, Shuping
    Zhang, Yueying
    Wang, Zhaopeng
    Huang, Shuhong
    Wang, Zhaoxia
    BMC CANCER, 2020, 20 (01)
  • [40] PI3K/Akt/mTOR inhibitors in breast cancer
    Joycelyn JX Lee
    Kiley Loh
    Yoon-Sim Yap
    Cancer Biology & Medicine, 2015, 12 (04) : 342 - 354